The multidrug regimen under the National Leprosy Eradication Programme for the treatment of all multibacillary leprosy would include –
💡 Explanation
## **Core Concept**
The National Leprosy Eradication Programme (NLEP) utilizes a multidrug therapy (MDT) regimen to treat leprosy effectively. Leprosy, also known as Hansen's disease, is caused by *Mycobacterium leprae*. The treatment regimen varies depending on the classification of the disease as paucibacillary or multibacillary.
## **Why the Correct Answer is Right**
The correct answer, , includes Rifampicin, Clofazimine, and Dapsone. This combination is specifically recommended by the World Health Organization (WHO) and adopted by the NLEP for the treatment of multibacillary leprosy.
- **Rifampicin** is a potent bactericidal agent against *M. leprae*.
- **Clofazimine** has both bactericidal and anti-inflammatory properties.
- **Dapsone** is bacteriostatic against *M. leprae* but is included for its effectiveness in combination therapy.
## **Why Each Wrong Option is Incorrect**
- **Option A:** - This option lacks Clofazimine, which is a critical component of the multibacillary regimen.
- **Option B:** - This option includes Ofloxacin, which is used in some leprosy treatment regimens but not in the standard NLEP multibacillary regimen.
- **Option D:** - This option does not include Clofazimine and replaces Dapsone with Ofloxacin, which is not standard for multibacillary leprosy treatment under NLEP.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the MDT regimen for multibacillary leprosy consists of Rifampicin (600 mg), Clofazimine (300 mg), and Dapsone (100 mg) once monthly for 12 months, supervised by healthcare workers. This combination is crucial for preventing drug resistance and ensuring effective treatment.